PDF(Pubmed)
Abstract：
UNASSIGNED: The introduction of HER2-targeting antibody drug conjugates (ADCs) offers new treatment options for female breast cancer patients (FBC) expressing low levels of HER2 (HER2 low). No evidence was found that HER2 low describes a new FBC subtype. There is a lack of studies determining the impact of HER2 low in male breast cancer (MBC). In this study, we evaluate the prevalence of HER2 low in primary MBC and correlate the results with patient characteristics.
UNASSIGNED: In this study, histological specimens were obtained from 120 male patients diagnosed and treated for primary invasive breast cancer from 1995 to 2022 at Breast Cancer Units in Bergisch Gladbach, Chemnitz, and Zwickau, Germany. HER2 immunostaining and in situ hybridization were performed by central pathology and evaluated based on the ASCO/CAP guidelines. The correlation of expression of HER2 low with tumor biological characteristics and patient outcomes was investigated.
UNASSIGNED: Out of all cases, four patients (3.3%) showed HER2 positivity (3+), 39 (32.5%) patients were classified as HER2 low, 7 (5.8%) were HER2 2+ (no amplification), 32 (26.7%) were HER2 1+, and 77 (64.2%) were classified as HER2 zero. Out of 77 HER2 zero cases, 47 tumors (61.0%) showed incomplete staining, with <10% of tumor cells classified as HER2 ultralow. No statistical correlation between HER2 low and tumor biological characteristics and patients\' survival was found.
UNASSIGNED: Our findings show a notable, albeit lower, prevalence of HER2 low expression in primary MBC. However, tumors expressing HER2 low do not show specific tumor biological features to define a new breast cancer subtype in MBC. Our results suggest that a significant number of MBC patients could benefit from ADCs, as shown in FBC. Further studies are required to better understand HER2 low breast cancer, both generally and in MBC.
UNASSIGNED: In this study, histological specimens were obtained from 120 male patients diagnosed and treated for primary invasive breast cancer from 1995 to 2022 at Breast Cancer Units in Bergisch Gladbach, Chemnitz, and Zwickau, Germany. HER2 immunostaining and in situ hybridization were performed by central pathology and evaluated based on the ASCO/CAP guidelines. The correlation of expression of HER2 low with tumor biological characteristics and patient outcomes was investigated.
UNASSIGNED: Out of all cases, four patients (3.3%) showed HER2 positivity (3+), 39 (32.5%) patients were classified as HER2 low, 7 (5.8%) were HER2 2+ (no amplification), 32 (26.7%) were HER2 1+, and 77 (64.2%) were classified as HER2 zero. Out of 77 HER2 zero cases, 47 tumors (61.0%) showed incomplete staining, with <10% of tumor cells classified as HER2 ultralow. No statistical correlation between HER2 low and tumor biological characteristics and patients\' survival was found.
UNASSIGNED: Our findings show a notable, albeit lower, prevalence of HER2 low expression in primary MBC. However, tumors expressing HER2 low do not show specific tumor biological features to define a new breast cancer subtype in MBC. Our results suggest that a significant number of MBC patients could benefit from ADCs, as shown in FBC. Further studies are required to better understand HER2 low breast cancer, both generally and in MBC.
摘要：
■HER2靶向抗体药物缀合物（ADC）的引入为表达低水平HER2（低HER2）的女性乳腺癌患者（FBC）提供了新的治疗选择。没有证据表明HER2低描述了一种新的FBC亚型。缺乏确定HER2低对男性乳腺癌（MBC）的影响的研究。在这项研究中,我们评估了原发性MBC中HER2低的患病率,并将结果与患者特征相关联.
■在这项研究中，组织学标本是从1995年至2022年在BergischGladbach的乳腺癌单位诊断和治疗的120名男性患者中获得的，Chemnitz,和Zwickau,德国。通过中心病理学进行HER2免疫染色和原位杂交，并根据ASCO/CAP指南进行评估。研究HER2低表达与肿瘤生物学特性和患者预后的相关性。
■在所有情况下，4例患者（3.3%）显示HER2阳性（3+），39例（32.5%）患者被归类为低HER2，7例（5.8%）为HER2+（无扩增），32例（26.7%）为HER21+，77（64.2%）被归类为HER2零。在77例HER2中，零病例，47例肿瘤（61.0%）染色不完全，<10%的肿瘤细胞被分类为HER2超低。HER2低与肿瘤生物学特征和患者生存期无统计学相关性。
■我们的研究结果表明，尽管更低，原发性MBC中HER2低表达的患病率。然而,低表达HER2的肿瘤不显示特定的肿瘤生物学特征来定义MBC中的新乳腺癌亚型。我们的结果表明，大量的MBC患者可以从ADC中受益，如FBC所示。需要进一步的研究来更好地了解HER2低乳腺癌，一般和MBC。
■在这项研究中，组织学标本是从1995年至2022年在BergischGladbach的乳腺癌单位诊断和治疗的120名男性患者中获得的，Chemnitz,和Zwickau,德国。通过中心病理学进行HER2免疫染色和原位杂交，并根据ASCO/CAP指南进行评估。研究HER2低表达与肿瘤生物学特性和患者预后的相关性。
■在所有情况下，4例患者（3.3%）显示HER2阳性（3+），39例（32.5%）患者被归类为低HER2，7例（5.8%）为HER2+（无扩增），32例（26.7%）为HER21+，77（64.2%）被归类为HER2零。在77例HER2中，零病例，47例肿瘤（61.0%）染色不完全，<10%的肿瘤细胞被分类为HER2超低。HER2低与肿瘤生物学特征和患者生存期无统计学相关性。
■我们的研究结果表明，尽管更低，原发性MBC中HER2低表达的患病率。然而,低表达HER2的肿瘤不显示特定的肿瘤生物学特征来定义MBC中的新乳腺癌亚型。我们的结果表明，大量的MBC患者可以从ADC中受益，如FBC所示。需要进一步的研究来更好地了解HER2低乳腺癌，一般和MBC。
